Advanced Molecular Oncology Testing: A Focus on Next Generation Sequencing Panels and Novel Genetic Technologies
This session will familiarize participants with the application and utility of molecular oncology testing. Participants learn the fundamental features of molecular testing platforms as faculty review clinical scenarios in which molecular testing is appropriate. In addition, participants will learn to interpret molecular test results and explain their clinical significance. Featured panels include sarcoma, hematology, neuro-oncology, and RNA sequencing.
Oncology Testing Overview From the Mayo Clinic Department of Laboratory Medicine & Pathology Perspective
Hematology from the “Panel” Perspective Panel Discussion
Add one of the pre-conference sessions to complement your Individualizing Medicine Conference experience.
Since 1997, Eric has been the Pharmacy Director at Mayo Clinic’s campus in Arizona. In this role, he provides strategic oversight and direction to over 170 Pharmacy employees caring for patents in Inpatient, Outpatient and Hematology/Oncology Infusion suite settings. Eric is an Assistant Professor of Pharmacy in the Mayo Clinic College of Medicine, the Operations Administrator for the Center for Individualized Medicine and the Department of Clinical Genomics. He is also the administrative lead for Mayo Clinic’s Drug Diversion Prevention Program and Opioid Prescribing Compliance efforts.
Dr. Sekulic focuses his research interests on developing translational approaches for the study of genomics in skin diseases: identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation as it relates to human skin disease. Dr. Sekulic has extensive and active involvement in basic and translational research as well as clinical trials, exemplified by his role as principal investigator on the ERIVANCE trial, leading to the FDA approval of vismodegib, the first hedgehog pathway inhibitor for treatment of basal cell carcinoma. Dr. Sekulic has served as a teacher and mentor for numerous residents and students and is a recipient of the Excellence in Teaching Recognition Award from Mayo Medical School.
As Associate Director for the Center for Individualized Medicine in Arizona, Dr. Sekulic leads the center's transition into patient care by introducing genomic-based products and services into the clinical practice as a means of differentiating Mayo Clinic patient care.
Breakthrough in Anesthesia: Modern Tests for Modern CareYvette N. Martin McGrew, M.D., Ph.D., Mayo Clinic
Dr. Yvette Martin McGrew completed her M.D.,Ph.D.at Mayo Clinic as a part of the NIH-funded Medical Scientist Training Program. Her pharmacology Ph.D. training on MTHFR and Aromatase Pharmacogenomics was under Richard Weinshilboum, M.D., a world-renowned leader in the area of pharmacogenomics. Her in-depth study of the genetics, molecular mechanisms and clinical association of polymorphisms in the genes MTHFR and Aromatase, led to identification of novel variants that affect function and emphasized genotype-phenotype relationships of genes associated with breast cancer. Dr. Martin McGrew completed her internal medicine internship at the University of Colorado, followed by Anesthesiology residency at Mayo Clinic, where she has been a staff anesthesiologist since 2012. Currently, as part of an anesthesia pharmacogenomics working group, she studies the genetic contribution to adverse outcomes observed in anesthesia.
Personalizing Palliative CareMark K. Edwin, M.D., Mayo Clinic
Dr. Edwin is a Palliative Medicine consultant and assistant professor of medicine at Mayo Clinic Arizona. His research and educational interests include opioid-induced hyperalgesia in advanced cancer patients, cancer pain management, bioethics and complex hospice cases. He completed his medical training at McGill University and Mayo Clinic.
Anticoagulants: History & FutureFadi E. Shamoun, M.D., Mayo Clinic
Dr. Shamoun is a consultant and assistant professor in the Department of Cardiovascular Diseases at Mayo Clinic’s campus in Arizona. His research interests include genetic factors in vascular disorders such as peripheral artery disease, aortic diseases, and the use of pharmacogenomics in cardiac patients. Dr. Shamoun is a physician champion for pharmacogenomics at the Center for Individualized Medicine in Arizona, and leads multiple clinical trials in his role. He received the Educator of the Year Award in Research in 2014, and continues to conduct research in vascular medicine and pharmacogenomics.
Q&A for the PanelMark K. Edwin, M.D., Yvette N. Martin, M.D., Ph.D, & Fadi E. Shamoun, M.D., Mayo Clinic
Native American Communities and PharmacogenomicsMira T. Keddis, M.D., Mayo Clinic
Dr. Keddis is a consultant and assistant professor of medicine in the Division of Nephrology & Hypertension at Mayo Clinic Arizona. Her research areas include cardiovascular risk assessment of kidney transplant candidates, cardiac biomarkers in the care and outcomes in kidney transplant patients, health disparities in access to care and outcomes in the Native American population, and the utility of cystatin C for assessment of graft function and clinical outcome in kidney transplant patients. She received the Clinomics-Pharmacogenomics Award from the Center for Individualized Medicine in 2018.
Taking it Personally: 2D6 and TamoxifenEric J. Yancey, Pharm.D., BCOP, Mayo Clinic
Dr. Yancey is a clinical pharmacy specialist and instructor in pharmacy at Mayo Clinic’s campus in Arizona. His research interests include the role of machine learning in predicting development of chemotherapy-induced cardiotoxicity, the use of pharmacogenomic testing in patients with hand-food skin reaction on tyrosine kinase inhibitors, and tolerance rates for intraperitoneal taxane/platinum doublet for ovarian and peritoneal cancer. He holds an ACCP Pharmacogenomics certification, and takes part in pharmacogenomic implementation efforts at Mayo Clinic Arizona.
Dr. Wang’s research is focused on pharmacogenomics, a critical component of individualized medicine that studies the role of inheritance in variation in drug response. Patients treated with the same dose or regimen of a drug can display different responses, ranging from lack of efficacy to severe toxicity. Dr. Wang's laboratory uses various high-throughput "omics" tools, including genomics, transcriptomics and metabolomics, to identify biomarkers that can help predict clinical response. At the same time, her lab uses various models, including cells, patient-derived xenografts and patient samples, to validate and understand the biology underlying these biomarkers.
Q&A with PanelModerator: Eric A. Nelson, R.Ph.,
Panel: Chris Grilli, Pharm.D., R.Ph., M.B.A., Eric J. Yancey, R.Ph. and Fadi E. Shamoun, M.D., Mayo Clinic
“Curbside” Attendee Case Discussion with the Experts (Optional session with Lunch Session Purchase)Moderator: Eric A. Nelson, R. Ph., Mayo Clinic
Oncolytic VirusesGrant McFadden, Ph.D., Arizona State University
Dr. McFadden is a researcher at Arizona State University’s Biodesign Institute specializing in the interactions between poxviruses and their host immune systems. The McFadden lab pioneered the field of immune subversion (also called “anti-immunology”), and is credited with the discovery of a wide spectrum of virus-derived inhibitors of the immune system. His lab also investigates host-virus tropism, and the deployment of poxviruses for oncolytic virotherapy for the treatment of cancer, particularly with a rabbit-specific poxvirus called myxoma virus (MYXV). He is also currently developing human clinical trials that exploit virotherapy with MYXV to improve hematopoietic stem cell transplantation therapies for cancer, in collaboration with the biotech company DNAtrix.
Computational GenomicsMelissa Wilson, Ph.D., Arizona State University
Dr. Wilson is a computational evolutionary biologist at Arizona State University whose main research interests include sex-based biology. She studies the evolution of sex chromosomes (X and Y in mammals), why mutation rates differ between males and females, and how changes in population history affect the sex chromosomes differently than the non-sex chromosomes. Dr. Wilson generally studies mammals but is also interested in the sex-based biology of flies, worms, and plants. Additionally, Dr. Wilson is active in public science engagement and outreach. She routinely teaches in K-12 classrooms, and regularly engages the public in discussions about the difference between sex and gender, the importance (or not) of genetic inheritance, and understanding evolution.
Pre-clinical Models of ImmunotherapiesKaren S. Anderson, M.D., PhD., Mayo Clinic/Arizona State University
Modeling Cancer Immunity: Colon CancerKhashayarsha Khazaie, Ph.D., Mayo Clinic
Dr. Khazaie directs basic and translational research in cancer immunology and immunosenescence. Dr. Khazaie's lab studies immune responses that help tumors grow and spread as well as immune responses that protect against cancer. A major focus is on regulatory T cells, their subsets, and their diverse functions in regulating inflammation and immunity in the gastrointestinal tract. In this context, there is interest in the role of microbiota and circadian rhythm. Breast cancer recurrence is a second topic of Dr. Khazaie’s research, wherein the role of the immune system in controlling tumor dissemination, tumor dormancy and metastasis is investigated. Novel microbial-based vaccines are tested for treatment of metastatic breast cancer. Dr. Khazaie is also interested in understanding how the immune system changes during the aging process and how these changes help to predispose the aging to cancer. Dr. Khazaie is dedicated to ensuring continually high-quality patient care through the education of current and future physicians and scientists, and carries out various teaching activities in the field of immunology.
Questions and Discussion with the Faculty
Cancer Vaccine DevelopmentKeith L. Knutson, Ph.D., Mayo Clinic
Immunotherapy and Neoantigens in CancerJanuario E. Castro, M.D., Mayo Clinic
Neoantigen Peptide Vaccines for Melanoma
Designing Clinical Pipelines for Precision ImmunotherapiesKaren S. Anderson, M.D., Mayo Clinic/Arizona State University
Questions and Discussion with the Faculty